Ryan Specialty has demonstrated exceptional growth with a 24.5% compounded annual growth rate over the past five years, showing strong demand across the business services sector. The company expects high single-digit organic revenue growth for 2026 with continued challenges in property pricing but confidence in modest margin expansion.
Cyborg Score Rationale
Q4 2025 results showed 13.2% year-on-year revenue growth but missed analyst expectations on both revenue and earnings per share. The stock has declined 18.54% in the past week with a market cap of $5.0 billion as of mid-February 2026. Recent strategic restructuring and margin pressures offset solid long-term growth trajectory.
Top Insights
The board approved a three-year 'Empower Program' restructuring beginning Q1 2026, expected to generate $80 million in annual savings by 2029.
Operating margin contracted to 12.2% in Q4 2025 from 16.5% year-over-year as expenses grew faster than revenue.
Management approved an 8% dividend increase and authorized a $300 million share repurchase program.
The company serves commercial, industrial, institutional, individual, and government sectors across multiple geographies.
Named Competitors
Marsh & McLennan — Global leader in insurance brokerage and risk management
Willis Towers Watson — Major insurance and benefits consultant
Gallagher — Large independent insurance broker and risk management services